NasdaqGM:NAMSBiotechs
How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses
In August 2026, NewAmsterdam Pharma reported second-quarter 2026 results showing sales of US$3.7 million versus US$19.15 million a year earlier, alongside a wider net loss of US$64.14 million compared with US$17.36 million.
Over the first half of 2026, the company’s sales fell to US$6.74 million while its net loss roughly doubled to US$112.58 million, highlighting rising costs against shrinking revenue.
Next, we examine how this sharp revenue drop and widening losses shape NewAmsterdam...